New York Assembly Bill A07944

New York 2025-2026 Regular Session

• Introduced: 4/16/25
• Refer: 4/16/25

Caption

Ensures continuity of care for cancer patients during insurance contract negotiations by requiring insurance coverage and treatment continue until the conclusion of care.

Impact

If enacted, A07944 would significantly alter the landscape of healthcare management in New York, particularly for cancer patients. It would require insurance companies to keep coverage active for patients undergoing oncology treatment even when disputes arise with hospitals. This change means that patients can expect uninterrupted care during a critical phase of their treatment regardless of administrative hurdles. By protecting patients' access to necessary medical services, the bill aims to alleviate concerns regarding financial and health-related stress associated with insurance disruptions.

Summary

Bill A07944, known as the Continuity of Cancer Care Act (COCCA), aims to ensure that patients receiving treatment for cancer do not experience disruptions in their care during contract negotiations between their hospitals and insurance providers. This legislation has been introduced to amend the existing insurance law and public health law by mandating insurers to continue coverage for cancer treatments if the insured and the hospital cannot reach an agreement during contract negotiations. The bill seeks to provide greater protections for patients during potentially tumultuous negotiations that could otherwise jeopardize their ongoing treatments.

Contention

Notable points of contention include the financial implications for insurance companies who may argue that this legislation could lead to increased costs. Opponents may express concerns that by requiring continued coverage during negotiations, the bill could inadvertently reduce the negotiating power of insurers. Advocates for the bill, however, argue that patient welfare must take precedence and that ensuring continuity of care is a fundamental right, especially for those battling cancer. Thus, the balance between patient rights and the operational flexibility of insurers remains a key issue in discussions surrounding the bill.